These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 11741098)

  • 1. Actigraph analysis of diurnal motor fluctuations during dopamine agonist therapy.
    Katayama S
    Eur Neurol; 2001; 46 Suppl 1():11-7. PubMed ID: 11741098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Objective measurement of motor activity in Parkinson's disease by actigraphy. Clinical assessment of akinesia].
    Fujikane M; Katayama S; Hirata K; Yokota N
    Nihon Rinsho; 1997 Jan; 55(1):153-7. PubMed ID: 9014441
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lifecorder: a new device for the long-term monitoring of motor activities for Parkinson's disease.
    Saito N; Yamamoto T; Sugiura Y; Shimizu S; Shimizu M
    Intern Med; 2004 Aug; 43(8):685-92. PubMed ID: 15468966
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations.
    Inzelberg R; Nisipeanu P; Rabey JM; Orlov E; Catz T; Kippervasser S; Schechtman E; Korczyn AD
    Neurology; 1996 Sep; 47(3):785-8. PubMed ID: 8797480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of cabergoline on parkinsonian tremor assessed by long-term actigraphy.
    Binder S; Deuschl G; Volkmann J
    Eur Neurol; 2009; 61(3):149-53. PubMed ID: 19092251
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease.
    Högl B; Rothdach A; Wetter TC; Trenkwalder C
    Neuropsychopharmacology; 2003 Oct; 28(10):1866-70. PubMed ID: 12865895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of cabergoline in long-term use: results of three observational studies in 1,500 patients with Parkinson's disease.
    Baas HK; Schueler P
    Eur Neurol; 2001; 46 Suppl 1():18-23. PubMed ID: 11741099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diurnal motor variations to repeated doses of levodopa in Parkinson's disease.
    Bonuccelli U; Del Dotto P; Lucetti C; Petrozzi L; Bernardini S; Gambaccini G; Rossi G; Piccini P
    Clin Neuropharmacol; 2000; 23(1):28-33. PubMed ID: 10682228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off.
    Deuschl G; Vaitkus A; Fox GC; Roscher T; Schremmer D; Gordin A;
    Mov Disord; 2007 Aug; 22(11):1550-5. PubMed ID: 17516484
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinicophysiological study of tremor in Parkinson's disease: quantitative tremor-based assessment of motor count using actigraphy].
    Mochio S; Oka H; Katayama K; Sato H
    Nihon Rinsho; 1997 Jan; 55(1):158-62. PubMed ID: 9014442
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Cabergoline in the treatment of Parkinson's disease].
    Pastor P; Tolosa E
    Neurologia; 2003 May; 18(4):202-9. PubMed ID: 12721865
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease.
    Linazasoro G;
    Clin Neuropharmacol; 2008; 31(1):19-24. PubMed ID: 18303487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cabergoline in Parkinson's disease: long-term follow-up.
    Lera G; Vaamonde J; Rodriguez M; Obeso JA
    Neurology; 1993 Dec; 43(12):2587-90. PubMed ID: 7902970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cabergoline improves motor disability without modifying L-dopa plasma levels in fluctuating Parkinson's disease patients.
    Del Dotto P; Colzi A; Pardini C; Lucetti C; Dubini A; Grimaldi R; Bonuccelli U
    J Neural Transm Suppl; 1995; 45():259-65. PubMed ID: 8748633
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Presynaptic mechanisms of motor fluctuations in Parkinson's disease: a probabilistic model.
    de la Fuente-Fernández R; Schulzer M; Mak E; Calne DB; Stoessl AJ
    Brain; 2004 Apr; 127(Pt 4):888-99. PubMed ID: 14960500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Motor fluctuations in Parkinson's disease.
    Weiner WJ
    Rev Neurol Dis; 2006; 3(3):101-8. PubMed ID: 17047575
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease.
    Inzelberg R; Nisipeanu P; Rabey MJ; Korczyn AD
    Mov Disord; 1995 Sep; 10(5):604-7. PubMed ID: 8552112
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessment of response fluctuations in Parkinson's disease by ambulatory wrist activity monitoring.
    van Hilten JJ; Kabel JF; Middelkoop HA; Kramer CG; Kerkhof GA; Roos RA
    Acta Neurol Scand; 1993 Mar; 87(3):171-7. PubMed ID: 8475685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entacapone in the treatment of Parkinson's disease.
    Schrag A
    Lancet Neurol; 2005 Jun; 4(6):366-70. PubMed ID: 15907741
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sweating in Parkinsonian patients with wearing-off.
    Pursiainen V; Haapaniemi TH; Korpelainen JT; Sotaniemi KA; Myllylä VV
    Mov Disord; 2007 Apr; 22(6):828-32. PubMed ID: 17357129
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.